TITLE

COGNITEST DIAGNOSTIC BLOOD TEST FOR ALZHEIMER'S MILESTONE

PUB. DATE
April 2011
SOURCE
Worldwide Biotech;Apr2011, Vol. 23 Issue 4, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports the completion of biOasis Technologies Inc. in April 2011 of a project aimed at producing proprietary monoclonal antibodies (mAbs) for its Cognitest (TM) blood test for Alzheimer's disease. Done in collaboration with Fleet Bioprocessing and Oxfabs, biOasis can reportedly begin the validation of Cognitest (TM) using clinical samples from North America and Europe. According to the article, an easy-to-use quantitative blood test will help physicians in diagnosing and combating Alzheimer's disease.
ACCESSION #
59633530

 

Related Articles

  • biOasis Tech, Fleet partner to develop Alzheimer's assay.  // Medical Device Daily;12/4/2009, Vol. 13 Issue 233, p3 

    The article reports on the agreement between biOasis Technologies and Fleet Bioprocessing in November 2009 to develop immunoassays for the diagnosis of Alzheimer's disease. The deal will allow biOasis to reduce product development for its p97 Alzheimer's test, shares company chief executive...

  • Achievement Reached in Alzheimer's Disease Test.  // Clinical Lab Products;Mar2011, Vol. 41 Issue 3, p12 

    The article reports on the completion of a project for Cognitest blood test for Alzheimer's disease by BiOasis Technologies of Vancouver, British Columbia in March 2011.

  • Alzheimer's Disease and Immunotherapy. Solomon, Beka // Current Alzheimer Research;Aug2004, Vol. 1 Issue 3, p149 

    Site-directed antibodies which modulate conformation of �-amyloid peptide became the theoretical basis of the immunological approach for treatment of Alzheimer's disease (AD). Indeed, antibodies towards the EFRH sequence, located between amino acids 3-6 of the N-terminal region of...

  • Potential use and sales for solanezumab in the US.  // PharmacoEconomics & Outcomes News;10/5/2013, Issue 688, p10 

    The article focuses on a report which revealed that U.S. neurologists would prescribe the monoclonal antibody solanezumab to patients with Alzheimer's disease.

  • Association Between Complement Regulatory Protein Factor H and AM34 Antigen, Detected in Senile Plaques. Honda, Saho; Itoh, Fumio // Journals of Gerontology Series A: Biological Sciences & Medical ;May2000, Vol. 55 Issue 5, pM265 

    Presents information on a study that investigated the expression of factor H in tissue from a human brain and the relation between AM34 antigen and factor H. Methodology; Expression of factor H in alzheimer's disease; Results; Conclusion.

  • IN VITRO ANALYSIS OF PAIRED HELICAL FILAMENTS FROM ALZHEIMER BRAIN TISSUE... Jicha, Gregory A.; Davies, Peter // Einstein Quarterly: Journal of Biology & Medicine;1998, Vol. 15 Issue 2, p109 

    Develops a method of immunoaffinity purifying paired helical filaments (PHF) under nondenaturing conditions from Alzheimer's disease (AD) brain homogenates using the monoclonal antibodies Alz-50 and MC-1. Major constituent of PHF in AD; Evidence of the altered conformation of tau in PHF; Role...

  • The Alzheimer's “breakthrough” drug that wasn't. McCartney, Margaret // BMJ: British Medical Journal;8/1/2015, Vol. 351 Issue 8019, p23 

    In the article, the author discusses developments in the healthcare sector in Great Britain as of August 2015, particularly the alleged creation of the breakthrough drug called solanezumab against Alzheimer's disease. She claims, however, that drug developer Eli Lilly has no significant data on...

  • Neurimmune Begins Phase 3 Program for Aducanumab for Early Alzheimer's Disease.  // Journal of Gerontological Nursing;2015, Vol. 41 Issue 12, p6 

    The article offers information on global phase 3 program of Neurimmune, biotechnology company, for the investigational treatment aducanumab and mentions the program includes placebo controlled studies, Engage and Emerge.

  • New therapy markedly reduces amyloid-β, the hallmark protein that leads to Alzheimer's.  // Canadian Nursing Home;Sep/Oct2016, Vol. 27 Issue 3, p27 

    No abstract available.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics